1-(乙基磺酰基)-3-[4-(7h-吡咯并[2,3-d]嘧啶-4-基)-1h-吡唑-1-基]-3-氮杂环丁烷乙腈;
baricitinib;incb28050;ly3009104;巴瑞替尼;baricitinib巴瑞克替尼;
巴瑞替尼(baricitinib);巴里西替尼;[巴瑞沙替尼]
1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]-3-azetidineacetonitrile;
incb 028050;ly 3009104;baricitinib (ly3009104);baricitinib/incb 028050/ly3009104;
baricitinib (ly3009104, incb028050);2-(3-(4-(3h-pyrrolo[2,3-d]pyrimidin-4-yl)
-1h-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2018年国际药学研究网宣布其全球Ⅲ期临床RA-BEACON试验每天口服1次巴瑞克替尼(baricitinib)治疗中重度类风湿关节炎达到主终点。该药是一种选择性JAK1和JAK2抑制剂,治疗12周时关节肿胀及触痛改善20%(ACR 20)的有效率,巴瑞克替尼4 mg组为55%,2 mg组为49%,安慰剂组为27%。临床RABEACON试验入选527名肿瘤坏死因子(TNF)抑制